Sodium nitroprusside (N-N2) injections, and the bioactive molecules that promote heart function, can reduce damage to the heart’s tissue, find a small pilot study of healthy volunteers. The results are published in JAMA Internal Medicine.
And in studies of two animals with implanted defibrillators, the researchers found that N-N2 elevations in heart muscle didn’t increase the rate of cell death, the process by which the heart stops working. Exercise and oral calcium treatment reduced this damage, suggesting the potential of N-N2 as a cardiovascular treatment option.
The results are published in JAMA Internal Medicine and bring new possibilities to preventing or minimizing heart damage linked to high blood pressure, diabetes and prolonged use of high-intensity continuous positive airway pressure (CICO) machines used in the office, hospital and sports stadium.
“The different results seen in our trial indicate a potential for N-N2 treatment to be used in combination with a CICO-interfering intervention to lower cardiovascular risk in high-risk patients,” said lead study author Connor Schwartz, MD, PhD, from Labadu Centre for Diabetes and Endocrinology in Melbourne, Australia.
Heart Failure and Type 2 Diabetes.
Inflammation and oxidative stress promote increased intracranial pressure and vasoconstriction (the narrowing of arteries), which builds up in the heart and impairs its ability to pump efficiently. This can cause heart failure, a chronic disease that increases the risk of heart rhythm problems, strokes and death.
CICO machines are highly effective with reduced calcium excretion, but doctors have not understood how N-N2 affects heart function and its potential as a therapy.
N-N2 is a naturally occlusive salt (about 30 percent by weight) widely used as a soluable component for pharmaceuticals, consumer products and food products. The most widely prescribed is oral N-N2/chloride hydrate (N-COO), derived from the urine of healthy patients with no signs of kidney stones, diabetes or kidney failure, including in type 2 diabetes (T2D).
In the placebo-controlled, randomized, double-blind, double-cross-over, randomized-controlled trial, the investigators switched from the N-COO to a placebo at 50 mg/kg within the first 3 hours after facility discharge.
Heart Failure and Metabolic Syndrome Patients.
The investigators investigated the effects of the N-N2/chloride N-N2−/− dose combination (N-COO/placebo) on blood pressure control and heart rhythm function in two groups of healthy volunteers (6-to-12-month follow-up of the second group) before dose escalation to peak heart failure (400 beats per minute or higher HRmax).Animals administered with a total of 90 doses (range 30-120 mg/kg) over 6 days followed by the 30-day intravenous N-N2/chloride N-N2−/− dose ratio supplement (N-N2/COO) were changed from a baseline mean arterial pressure reading (PAPR, 120 mm Hg) to one that represents the peak systolic (SBP) pressure (SBP=0.90-2.05 mHg).Values were assessed at 12-point heart rate ratios at up to 3 hours after dose escalation.
Results showed that the combination significantly (P < .01) lowered both mean SBP and peak peak systolic HR (+0.7 to 0.24 mm Hg) in the treated group, and this effect did not significantly differ by race (P =.00). There also no differences in SBP and peak timing (P =.67). The dose-escalation test was repeated as an eight-hour washout period. No dose-escalation effect on other markers of heart function. Although the effects of the combination were statistically significant, there was no application of the result. For example, mean mean heart rate in the treated group was 0.90 ± 0.02 mHg and peak systolic HR was 0.81 ± 0.06 mm Hg after 5-second N-N2/chloride/−9-day treatment, similar to a change of 0.62 mm Hg in the placebo-Patient 1/3 treatment group. Higher doses of N-N2/chloride N-N2−/− at the start of treatment (75–250 mg/kg) and extension thereof (450–750 mg/kg) resulted in dose-escalation effects on both SBP and peak HR at 6 months, but no statistically significant elevation of M2 (g/min) or MG (g/min) at 6 months. It is not recommended to take tablets in a dose of more than 20 mg. Even taking 60 mg of tadalafil significantly enhances side effects. The main symptoms of an overdose after tadalafil 20 mg india are headaches and dizziness, nasal congestion, and blurred vision. In case of an overdose, symptomatic treatment is required.
